Patents by Inventor Hermann Russ

Hermann Russ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition comprising botulinum toxin
    Patent number: 11969461
    Abstract: The present invention concerns a composition comprising (a) botulinum toxin and (b) non-crosslinked hyaluronic acid and its use of the treatment or prevention of dystonia, spasticity and/or wrinkles. Further, the present invention relates to a method for cosmetically smoothing or preventing wrinkles comprising the step of administering the present composition.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 30, 2024
    Assignee: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Klaus Fink, Harold Taylor, Hermann Russ, Peter Boderke
  • INDOLE COMPOUNDS FOR USE IN NEURORESTORATION
    Publication number: 20220193035
    Abstract: Provided herein are methods of use of indole derivative compounds for reversal of amyloid ? toxicity in amyloid ?-associated diseases.
    Type: Application
    Filed: April 23, 2020
    Publication date: June 23, 2022
    Applicant: Galimedix Therapeutics, Inc.
    Inventors: Christopher Graham Raphael. Parsons (Deceased), Gerhard Rammes, Hermann Russ, Andrew L Pearlman
  • Methods for the treatment of glaucoma and age-related macular degeneration by a peptide D-TRP-AIB
    Patent number: 10987400
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.
    Type: Grant
    Filed: December 1, 2019
    Date of Patent: April 27, 2021
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD
    Inventor: Hermann Russ
  • Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease
    Publication number: 20200121812
    Abstract: The present invention relates to new combinations of treatments for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-O-methyltransferase (COMT) inhibitors.
    Type: Application
    Filed: August 29, 2019
    Publication date: April 23, 2020
    Inventors: Hermann Russ, Silvia A. Mandel, Aric Orbach
  • THE USE OF SUBSTANCES FOR THE TREATMENT OF LOSS OF EYESIGHT IN HUMANS WITH GLAUCOMA AND OTHER DEGENERATIVE EYE DISEASES
    Publication number: 20200085906
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.
    Type: Application
    Filed: December 1, 2019
    Publication date: March 19, 2020
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventor: HERMANN RUSS
  • Methods for the treatment of glaucoma and age-related macular degeneratiion by a peptide D-TRP-AIB
    Patent number: 10525097
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Ramot at Tel Aviv University Ltd
    Inventor: Hermann Russ
  • COMPOSITION COMPRISING BOTULINUM TOXIN
    Publication number: 20190060422
    Abstract: The present invention concerns a composition comprising (a) botulinum toxin and (b) non-crosslinked hyaluronic acid and its use of the treatment or prevention of dystonia, spasticity and/or wrinkles. Further, the present invention relates to a method for cosmetically smoothing or preventing wrinkles comprising the step of administering the present composition.
    Type: Application
    Filed: February 28, 2017
    Publication date: February 28, 2019
    Inventors: Klaus FINK, Harold TAYLOR, Hermann RUSS, Peter BODERKE
  • Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
    Patent number: 9717772
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: August 1, 2017
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Hermann Russ, Wojciech Danysz, Christopher Graham Raphael Parsons
  • Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease
    Publication number: 20170165381
    Abstract: The present invention relates to new combinations of treatments for abnormal dopamine deficiency disorders, and related conditions, comprising deuterated catecholamine derivatives and catechol-O-methyltransferase (COMT) inhibitors.
    Type: Application
    Filed: January 9, 2017
    Publication date: June 15, 2017
    Inventors: Hermann Russ, Silvia A. Mandel, Aric Orbach
  • USE OF SUBSTANCES FOR THE TREATMENT OF LOSS OF EYESIGHT IN HUMANS WITH GLAUCOMA AND OTHER DEGENERATIVE EYE DISEASES
    Publication number: 20170065664
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.
    Type: Application
    Filed: November 17, 2016
    Publication date: March 9, 2017
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventor: Hermann RUSS
  • INTERVAL THERAPY FOR THE TREATMENT OF LOSS OF EYESIGHT IN HUMANS WITH GLAUCOMA AND OTHER DEGENERATIVE EYE DISEASES
    Publication number: 20160038558
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.
    Type: Application
    Filed: June 20, 2013
    Publication date: February 11, 2016
    Inventors: Hermann RUSS, Wojciech DANYSZ, Christopher Graham Raphael FARSONS
  • ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA
    Publication number: 20110288105
    Abstract: The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in Parkinson's patients, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2009
    Publication date: November 24, 2011
    Applicant: Merz Pharma GmbH & Co. KGaA
    Inventors: Barbara Valastro, Andrzej Dekundy, Frank Tennigkeit, Hermann Russ, Lutz Franke
  • Use of(R)-(?) -2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
    Patent number: 7928128
    Abstract: (R)-(?)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof is useful for treatment of adverse effects in treating Parkinson's disease.
    Type: Grant
    Filed: February 1, 2001
    Date of Patent: April 19, 2011
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Gerd Bartoszyk, Hermann Russ, Christoph Seyfried, Frank Weber
  • Use of substituted aminomethyl chromans
    Patent number: 7618988
    Abstract: Compounds of formula I in which R has a meaning as indicated in claim 1, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: November 17, 2009
    Assignee: Merck Patentgesellschaft
    Inventors: Henning Böttcher, Ralf Devant, Maria Devant, legal representative, Gerd Bartoszyk, Hermann Russ, Frank Weber, Christoph Seyfried
  • Novel use of substituted aminomethyl chromans
    Publication number: 20060229339
    Abstract: Compounds of formula I in which R has a meaning as indicated in claim 1, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics.
    Type: Application
    Filed: August 12, 2002
    Publication date: October 12, 2006
    Inventors: Henning Böttcher, Ralf Devant, Maria Devant, Gerd Bartoszyk, Hermann Russ, Frank Weber, Christoph Seyfried
  • Novel use of substituted aminomethyl chromans for the treatment of movement disorders and of adverse effects induced by drugs administered to treat extrapyramidal movement disorders
    Publication number: 20040235920
    Abstract: Substituted aminomethyl chromans, one of their optical isomers or pharmaceutically acceptable salts, used for the manufacture of a medicament for the treatment of adverse effects of anti-Parkinsonian drugs in extrapyramidal movement disorders and/or for the manufacture of a medicament for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics. A preferred compound is (−)-(R)-2-{4-[[3,4-dihydro-2H-benzopyran-2-yl)-methyl!amino!butyl}-1,2-benzoisothiazol-3-(2H)-on-1,1-dioxide or a physiologically acceptable salt thereof.
    Type: Application
    Filed: March 11, 2004
    Publication date: November 25, 2004
    Inventors: Gerd Bartoszyk, Henning Bottcher, Christoph Seyfried, Hermann Russ, Heinz-Hermann Bokel, Uschi Schmid-Grobmann
  • Novel use of(r) -(-) -2-[5-(4-fluorophenyl)-3- pyridylmethylaminomethy]-chromane and its physiologically acceptable salts )
    Publication number: 20030181486
    Abstract: (R)-(−)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders. A preferred salt is (R)-(−)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane hydrochloride.
    Type: Application
    Filed: December 30, 2002
    Publication date: September 25, 2003
    Inventors: Gerd Bartoszyk, Hermann Russ, Christoph Seyfried, Frank Weber